Alexandra Kropotova - 14 Mar 2023 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Chief Medical Officer
Signature
/s/ Alexandra Kropotova
Issuer symbol
SABS
Transactions as of
14 Mar 2023
Net transactions value
$0
Form type
4
Filing time
16 Mar 2023, 16:30:22 UTC
Previous filing
15 Sep 2022
Next filing
23 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SABS Common Stock Award +275,000 275,000 14 Mar 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Unit ("RSU") award under the 2021 Equity Incentive Plan, which vests over a four-year service period, with the first 25% vesting on March 14, 2024, and the remaining vesting in even monthly increments thereafter. The RSU award is subject to the reporting person's continued employment through the vesting date.
F2 Each RSU represents a contingent right to receive one share of the Issuer's common stock.